Recent scientific investigations explore the repurposing of the anti-parasitic drug fenbendazole as a novel treatment for oncological diseases, specifically targeting breast cancer. The primary purpose of the study is to evaluate how this medication influences the cellular redox status and viability of malignant cell lines compared to healthy ones. By exposing normal breast cells and various cancer lines to the compound, researchers discovered that it induces significant oxidative stress in aggressive tumor cells while suppressing reactive oxygen species in healthy epithelial tissue. Ultimately, the findings suggest that the medication operates through distinct redox mechanisms depending on the cancer type, highlighting its potential as a targeted, tumor-selective therapeutic agent.
Based on the study by Semkova et al. (2023) in Anticancer Research, the anticancer activity of the veterinary anthelmintic fenbendazole involves multiple interconnected mechanisms, with a particular emphasis on tumor-selective redox modulation and differential metabolic vulnerability.


